ATS 2024 Final Program

Click on the session title to view the speakers

96

SUNDAY • MAYs 19

12:15 CATCH: Creating Access To Transplant For Candidates Who Are High Risk 12:30 Lung Transplant Recipient Exosome Phenotypes and the Risk Of Primary Graft Dysfunction and sAcute Lung Allograft Dysfunction 12:45 Vaccination Responses In Lung Transplant Recipients

conclude with a general discussion on future directions and needs for rare lung disease research. 12:00 Introduction to the GDMCC 12:05 Cross-Sectional Study Defining the Genetic Bases of Non-Cystic Fibrosis Suppurative Lung Disease 12:20 Longitudinal Study Assessing the Effect of Respiratory Exacerbations on Quality of Life and Disease Progression 12:35 Cross-Sectional Study Examining and Comparing the Clinical Impact of the Otolaryngological Manifestations of PCD and PID 12:50 Discussion

NHLBI, NIH MID-DAY SESSION

MD13 TWO DECADES OF PROGRESS FROM THE GENETIC DISORDERS OF MUCOCILIARY CLEARANCE CONSORTIUM 12:00 p.m. - 1:00 p.m. Marriott Marquis San Diego Marina Pacific Ballroom 18-19 (Ground Floor, North Tower) Target Audience Physician scientists, health providers, researchers, clinicians, nurses and educators interested in primary ciliary dyskinesia, non-cystic fibrosis bronchectasis and other disorders of mucociliary clearance. Junior professionals interested in rare lung disease Objectives At the conclusion of this session, the participant will be able to: • learn new technologies to investigate the pathogenic mechanisms and prediction of rare suppurative lung diseases • understand the pathogenesis, genetic, and risk factors for exacerbations in rare suppurative lung diseases in order to have new stratigies to manage the care of patients with these diseases • improve clinical phenotyping for rare suppurative lung diseases to be able to better diagnose patients with these diseases This session will focus on rare lung disease research with presentations highlighting past and recent progress from cohort studies within the Genetic Disorders of Mucociliary Clearance Consortium (GDMCC). Study teams will provide a a summary of diverse disease phenotypes, genetics, disease burden and influence of exacerbation risk factors for rare suppurative lung diseases. The scientific talks from the GDMCC will focus on progress made during the last five years from three cross-sectional and/or longitudinal studies. The session will

PEDIATRIC CLINICAL CORE CURRICULUM

PCC1 PEDIATRIC CLINICAL CORE CURRICULUM 1 12:00 p.m. - 1:00 p.m.

San Diego Convention Center Ballroom 20A (Upper Level)

Target Audience: All attendees Objectives

At the conclusion of this session, the participant will be able to: • discuss the management of pediatric ARDS, massive hemoptysis, and severe asthma in the ICU • explain the role of the pediatric pulmonologist in a cardiovascular ICU • identify strategies to approach discussions around tracheostomy and for planning effective transition out of the ICU The goal of the core is to support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements. The ATS Clinical Core Curriculum Symposia focus on key topics in the areas of Adult and Pediatric Pulmonary, Critical Care, and Sleep Medicine. The topics are aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to help clinicians stay up to date with important information relevant to their medical practices, and to provide an opportunity for clinicians to evaluate their individual knowledge and skills while earning MOC Medical Knowledge points 12:00 Staying Current: Updates in Pediatric ARDS Diagnosis and Management 12:25 Navigating Severe Asthma in the PICU 12:50 Question and Answer

ATS 2024 Conference Program • San Diego, CA